Acute Myeloid Leukemia Cells Express ICOS Ligand to Promote the Expansion of Regulatory T Cells
Yixiang Han, Yuqing Dong, Qianqian Yang, Wanling Xu, Songfu Jiang, Zhijie Yu, Kang Yu, Shenghui Zhang, Yixiang Han, Yuqing Dong, Qianqian Yang, Wanling Xu, Songfu Jiang, Zhijie Yu, Kang Yu, Shenghui Zhang
Abstract
CD4+CD25+Foxp3+ regulatory T cells (Tregs) accumulate in bone marrow microenvironment in acute myeloid leukemia (AML). However, little is known about how the tumor environment including tumor cells themselves affects this process. Here we demonstrated that AML cells expressed inducible T-cell costimulator ligand (ICOSL) that can provide costimulation through ICOS for the conversion and expansion of Tregs sustaining high Foxp3 and CD25 expression as well as a suppressive function. TNF-a stimulation up-regulated the expression of ICOSL. Furthermore, both the conversion and expansion of CD4+CD25+Foxp3+ T cells and CD4+ICOS+Foxp3+ T cells were induced by co-culture with AML cells overexpressed ICOSL. CD4+CD25+ICOS+ T cells possessed stronger ability to secrete IL-10 than CD4+CD25+ICOS- T cells. The mechanism by which IL-10 promoted the proliferation of AML cells was dependent on the activation of the Akt, Erk1/2, p38, and Stat3 signaling pathways. Blockade of ICOS signaling using anti-ICOSL antibody impaired the generation of Tregs and retarded the progression of an AML mice model injected with C1498 cells. The expression of ICOSL of patient AML cells and ICOS+ Tregs were found to be predictors for overall survival and disease-free survival in patients with AML, with ICOS+ Treg cell subset being a stronger predictor than total Tregs. These results suggest that ICOSL expression by AML cells may directly drive Treg expansion as a mechanism of immune evasion and ICOS+ Treg cell frequency is a better prognostic predictor in patients with AML.
Keywords: acute myeloid leukemia; inducible T-cell costimulator; inducible T-cell costimulator ligand; interleukin-10; regulatory T cells.
Figures
References
- Maynadie M, Girodon F, Manivet-Janoray I, Mounier M, Mugneret F, Bailly F, et al. . Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d'Or (Burgundy, France). Haematologica (2011) 96:55–61. 10.3324/haematol.2010.026252
- Konopleva MY, Jordan CT. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol. (2011) 29:591–9. 10.1200/JCO.2010.31.0904
- Campbell DJ, Koch MA. Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat Rev Immunol. (2011) 11:119–30. 10.1038/nri2916
- Ooi JD, Petersen J, Tan YH, Huynh M, Willett ZJ, Ramarathinam SH, et al. . Dominant protection from HLA-linked autoimmunity by antigen-specific regulatory T cells. Nature (2017) 545:243–7. 10.1038/nature22329
- Cai S, Hou J, Fujino M, Zhang Q, Ichimaru N, Takahara S, et al. . iPSC-derived regulatory dendritic cells inhibit allograft rejection by generating alloantigen-specific regulatory T cells. Stem Cell Rep. (2017) 8:1174–89. 10.1016/j.stemcr.2017.03.020
- Facciabene A, Motz GT, Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res. (2012) 72:2162–71. 10.1158/0008-5472.CAN-11-3687
- Overacre-Delgoffe AE, Chikina M, Dadey RE, Yano H, Brunazzi EA, Shayan G, et al. . Interferon-gamma drives treg fragility to promote anti-tumor immunity. Cell (2017) 169:1130–41 e11. 10.1016/j.cell.2017.05.005
- Saito T, Nishikawa H, Wada H, Nagano Y, Sugiyama D, Atarashi K, et al. . Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med. (2016) 22:679–84. 10.1038/nm.4086
- Shenghui Z, Yixiang H, Jianbo W, Kang Y, Laixi B, Yan Z, et al. . Elevated frequencies of CD4+ CD25+ CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia. Int J Cancer (2011) 129:1373–81. 10.1002/ijc.25791
- Valzasina B, Piconese S, Guiducci C, Colombo MP. Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent. Cancer Res. (2006) 66:4488–95. 10.1158/0008-5472.CAN-05-4217
- Busse M, Krech M, Meyer-Bahlburg A, Hennig C, Hansen G. ICOS mediates the generation and function of CD4+CD25+Foxp3+ regulatory T cells conveying respiratory tolerance. J Immunol. (2012) 189:1975–82. 10.4049/jimmunol.1103581
- Lee HJ, Kim SN, Jeon MS, Yi T, Song SU. ICOSL expression in human bone marrow-derived mesenchymal stem cells promotes induction of regulatory T cells. Sci Rep. (2017) 7:44486. 10.1038/srep44486
- Thornton AM, Korty PE, Tran DQ, Wohlfert EA, Murray PE, Belkaid Y, et al. . Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol. (2010) 184:3433–41. 10.4049/jimmunol.0904028
- Redpath SA, van der Werf N, Cervera AM, MacDonald AS, Gray D, Maizels RM, et al. . ICOS controls Foxp3+ regulatory T-cell expansion, maintenance and IL-10 production during helminth infection. Eur J Immunol. (2013) 43:705–15. 10.1002/eji.201242794
- Le KS, Thibult ML, Just-Landi S, Pastor S, Gondois-Rey F, Granjeaud S, et al. . Follicular B lymphomas generate regulatory T cells via the ICOS/ICOSL pathway and are susceptible to treatment by anti-ICOS/ICOSL therapy. Cancer Res. (2016) 76:4648–60. 10.1158/0008-5472.CAN-15-0589
- Dong C, Juedes AE, Temann UA, Shresta S, Allison JP, Ruddle NH, et al. . ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature (2001) 409:97–101. 10.1038/35051100
- Nagase H, Takeoka T, Urakawa S, Morimoto-Okazawa A, Kawashima A, Iwahori K, et al. . ICOS+ Foxp3+ TILs in gastric cancer are prognostic markers and effector regulatory T cells associated with Helicobacter pylori. Int J Cancer (2017) 140:686–95. 10.1002/ijc.30475
- Tamura H, Dan K, Tamada K, Nakamura K, Shioi Y, Hyodo H, et al. . Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia. Clin Cancer Res. (2005) 11:5708–17. 10.1158/1078-0432.CCR-04-2672
- Dolen Y, Esendagli G. Myeloid leukemia cells with a B7-2+ subpopulation provoke Th-cell responses and become immuno-suppressive through the modulation of B7 ligands. Eur J Immunol. (2013) 43:747–57. 10.1002/eji.201242814
- Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. . The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood (2009) 114:937–51. 10.1182/blood-2009-03-209262
- Wu J, Hu G, Dong Y, Ma R, Yu Z, Jiang S, et al. . Matrine induces Akt/mTOR signalling inhibition-mediated autophagy and apoptosis in acute myeloid leukaemia cells. J Cell Mol Med. (2017) 21:1171–81. 10.1111/jcmm.13049
- Raynor J, Karns R, Almanan M, Li KP, Divanovic S, Chougnet CA, et al. . IL-6 and ICOS antagonize bim and promote regulatory T cell accrual with age. J Immunol. (2015) 195:944–52. 10.4049/jimmunol.1500443
- Gao Y, Xu B, Zhang P, He Y, Liang X, Liu J, et al. . TNF-alpha regulates mast cell functions by inhibiting cell degranulation. Cell Physiol Biochem. (2017) 44:751–62. 10.1159/000485288
- Tsimberidou AM, Estey E, Wen S, Pierce S, Kantarjian H, Albitar M, et al. . The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Cancer (2008) 113:1605–13. 10.1002/cncr.23785
- Wang M, Zhang C, Tian T, Zhang T, Wang R, Han F, et al. . Increased regulatory T cells in peripheral blood of acute myeloid leukemia patients rely on tumor necrosis factor (TNF)-alpha-TNF Receptor-2 Pathway. Front. Immunol. (2018) 9:1274. 10.3389/fimmu.2018.01274
- Sun C, Mezzadra R, Schumacher TN. Regulation and Function of the PD-L1 Checkpoint. Immunity (2018) 48:434–52. 10.1016/j.immuni.2018.03.014
- Martin-Orozco N, Li Y, Wang Y, Liu S, Hwu P, Liu YJ, et al. . Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells. Cancer Res. (2010) 70:9581–90. 10.1158/0008-5472.CAN-10-1379
- Burmeister Y, Lischke T, Dahler AC, Mages HW, Lam KP, Coyle AJ, et al. . ICOS controls the pool size of effector-memory and regulatory T cells. J Immunol. (2008) 180:774–82. 10.4049/jimmunol.180.2.774
- Curti A, Pandolfi S, Valzasina B, Aluigi M, Isidori A, Ferri E, et al. . Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood (2007) 109:2871–7. 10.1182/blood-2006-07-036863
- Curti A, Trabanelli S, Onofri C, Aluigi M, Salvestrini V, Ocadlikova D, et al. . Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells. Haematologica (2010) 95:2022–30. 10.3324/haematol.2010.025924
- Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, et al. . Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity (2009) 30:899–911. 10.1016/j.immuni.2009.03.019
- Gotsman I, Grabie N, Gupta R, Dacosta R, MacConmara M, Lederer J, et al. . Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation (2006) 114:2047–55. 10.1161/CIRCULATIONAHA.106.633263
- Kornete M, Sgouroudis E, Piccirillo CA. ICOS-dependent homeostasis and function of Foxp3+ regulatory T cells in islets of nonobese diabetic mice. J Immunol. (2012) 188:1064–74. 10.4049/jimmunol.1101303
- Conrad C, Gregorio J, Wang YH, Ito T, Meller S, Hanabuchi S, et al. . Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3+ T-regulatory cells. Cancer Res. (2012) 72:5240–9. 10.1158/0008-5472.CAN-12-2271
Source: PubMed